Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 18Gastrointestinal 15Thoracic 6Head & Neck 5Other solid neoplasm 4Tumor-Agnostic 3Sarcoma 3Breast 3Genitourinary 2Endocrine 2Dermatologic 1CNS 1

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 2Pathologic Complete Response 1Neoplasms 1Hemangiosarcoma 1

Interventions

Trastuzumab 349Paclitaxel 310Cyclophosphamide 286Docetaxel 267Carboplatin 215Capecitabine 215Letrozole 185Fulvestrant 178Doxorubicin 166Bevacizumab 136Anastrozole 120Tamoxifen 117pertuzumab 114pembrolizumab 113Epirubicin 110exemestane 107Vinorelbine 106Gemcitabine 106Albumin-Bound Paclitaxel 92Lapatinib 84130-nm albumin-bound paclitaxel 83Radiotherapy 79palbociclib 75eribulin 73Cisplatin 69pyrotinib 66Taxes 65Everolimus 55Goserelin 50Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × dostarlimab × Breast × Clear all
NCT04584255 2026-05-13

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
62 enrolled
Breast

Breast Neoplasms

NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT04837209 2025-10-01

NADiR

Massachusetts General Hospital

Phase 2 Active not recruiting
32 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡